BioSpace News Archive

[27-July-2020] DETROIT , July 27, 2020 /PRNewswire/ -- Guardhat today announced its participation in the Eurofins SAFER@WORK TM program; a collection of testing, tracing, and analysis tools developed to enhance workplace safety measures in accordance with U.S. CDC (Center for Disease Control and Prevention) guidelines.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report second quarter 2020 financial results after the Nasdaq Global Market close on Monday, August 10, 2020. About Catabasis At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients

Phase 2b results show that treatment with jCell was well-tolerated and demonstrated encouraging evidence of potential benefit in patients as an investigational treatment for retinitis pigmentosa agnostic to genetic subtype Based on these results, jCyte plans to initiate a pivotal study in 2021 jCell is a first-in-class investigational treatment which has received Regenerative Medicine Advanced Therapy (RMAT) designation from the US Food and Dr